Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies
Abstract
:1. Introduction
2. Materials and Methods
2.1. Laboratory Tests Analyzes
2.2. Imaging Procedure
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Woldeamanuel, Y.W.; Cowan, R.P. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. J. Neurol. Sci. 2017, 372, 307–315. [Google Scholar] [CrossRef]
- Edvinsson, L.; Haanes, K.A.; Warfvinge, K. Does inflammation have a role in migraine? Nat. Rev. Neurol. 2019, 15, 483–490. [Google Scholar] [CrossRef]
- Spekker, E.; Tanaka, M.; Szabó, Á.; Vécsei, L. Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research. Biomedicines 2021, 10, 76. [Google Scholar] [CrossRef]
- Ramachandran, R. Neurogenic inflammation and its role in migraine. Semin. Immunopathol. 2018, 40, 301–314. [Google Scholar] [CrossRef] [PubMed]
- Williamson, D.J.; Hargreaves, R.J. Neurogenic inflammation in the context of migraine. Microsc. Res. Tech. 2001, 53, 167–178. [Google Scholar] [CrossRef] [PubMed]
- Pietrobon, D. Migraine: New molecular mechanisms. Neuroscientist 2005, 11, 373–386. [Google Scholar] [CrossRef]
- Welch, K.M.; Brandes, A.W.; Salerno, L.; Brandes, J.L. C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 2006, 46, 197–199. [Google Scholar] [CrossRef]
- Tuca, J.O.; Planas, J.M.; Parellada, P.P. Increase in PGE2 and TXA2 in the saliva of common migraine patients. Action of calcium channel blockers. Headache 1989, 29, 498–501. [Google Scholar] [CrossRef]
- Vanmolkot, F.H.; de Hoon, J.N. Increased C-reactive protein in young adult patients with migraine. Cephalalgia 2007, 27, 843–846. [Google Scholar] [CrossRef]
- Yucel, Y.; Tanriverdi, H.; Arıkanoglu, A.; Varol, S.; Kaplan, I.; Akil, E.; Celepkolu, T.; Uzar, E. Increased fibrinogen, D-dimer and galectin-3 levels in patients with migraine. Neurol. Sci. 2014, 35, 545–549. [Google Scholar] [CrossRef] [PubMed]
- Park, J.Y.; Pillinger, M.H.; Abramson, S.B. Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. Clin. Immunol. 2006, 119, 229–240. [Google Scholar] [CrossRef]
- Antonova, M.; Wienecke, T.; Olesen, J.; Ashina, M. Prostaglandins in migraine: Update. Curr. Opin. Neurol. 2013, 26, 269–275. [Google Scholar] [CrossRef] [PubMed]
- Mozafarihashjin, M.; Togha, M.; Ghorbani, Z.; Farbod, A.; Rafiee, P.; Martami, F. Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: A case-control study with a focus on NGF, BDNF, VEGF, and PGE2. J. Headache Pain 2022, 23, 3. [Google Scholar] [CrossRef] [PubMed]
- Arita, M.; Yoshida, M.; Hong, S.; Tjonahen, E.; Glickman, J.N.; Petasis, N.A.; Blumberg, R.S.; Serhan, C.N. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 2005, 102, 7671–7676. [Google Scholar] [CrossRef] [PubMed]
- Ramsden, C.E.; Zamora, D.; Faurot, K.R.; MacIntosh, B.; Horowitz, M.; Keyes, G.S.; Yuan, Z.-X.; Miller, V.; Lynch, C.; Honvoh, G.; et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: Randomized controlled trial. BMJ 2021, 374, n1448. [Google Scholar] [CrossRef] [PubMed]
- Serhan, C.N. Systems approach to inflammation resolution: Identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. 2009, 7 (Suppl. S1), 44–48. [Google Scholar] [CrossRef] [PubMed]
- Godson, C.; Mitchell, S.; Harvey, K.; Petasis, N.A.; Hogg, N.; Brady, H.R. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 2000, 164, 1663–1667. [Google Scholar] [CrossRef] [PubMed]
- Fiore, S.; Serhan, C.N. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 1990, 172, 1451–1457. [Google Scholar] [CrossRef]
- Kahnt, A.S.; Schebb, N.H.; Steinhilber, D. Formation of lipoxins and resolvins in human leukocytes. Prostaglandins Other Lipid Mediat. 2023, 166, 106726. [Google Scholar] [CrossRef]
- Kooij, G.; Troletti, C.D.; Leuti, A.; Norris, P.C.; Riley, I.; Albanese, M.; Ruggieri, S.; Libreros, S.; van der Pol, S.M.; Hof, B.v.H.; et al. Specialized pro-resolving lipid mediators are differentially altered in the peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica 2020, 105, 2056–2070. [Google Scholar] [CrossRef]
- IHS Classification ICHD-3 The International Classification of Headache Disorders 3rd edition (Beta Version). Internet. Available online: https://ichd-3.org/ (accessed on 11 November 2020).
- Pardutz, A.; Schoenen, J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals 2010, 3, 1966–1987. [Google Scholar] [CrossRef]
- Tułowiecka, N.; Kotlęga, D.; Bohatyrewicz, A.; Szczuko, M. Could Lipoxins Represent a New Standard in Ischemic Stroke Treatment? Int. J. Mol. Sci. 2021, 22, 4207. [Google Scholar] [CrossRef]
- Farooqui, A.A. Lipid mediators and their metabolism in the nucleous: Implications for Alzheimer’s disease. J. Alzheimers. Dis. 2012, 30 (Suppl. S2), S163–S178. [Google Scholar] [CrossRef] [PubMed]
- Wu, L.; Liu, Z.J.; Miao, S.; Zou, L.B.; Cai, L.; Wu, P.; Ye, D.Y.; Wu, Q.; Li, H.H. Lipoxin A4 ameliorates cerebral ischaemia/reperfusion injury through upregulation of nuclear factor erythroid 2-related factor 2. Neurol. Res. 2013, 35, 968–975. [Google Scholar] [CrossRef] [PubMed]
- Wu, L.; Miao, S.; Zou, L.B.; Wu, P.; Hao, H.; Tang, K.; Zeng, P.; Xiong, J.; Li, H.-H.; Wu, Q.; et al. Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury. J. Mol. Neurosci. 2012, 48, 185–200. [Google Scholar] [CrossRef] [PubMed]
- Hawkins, K.E.; DeMars, K.M.; Alexander, J.C.; Leon, L.G.; Pacheco, S.C.; Graves, C.; Yang, C.; McCrea, A.O.; Frankowski, J.C.; Garrett, T.J.; et al. Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A4 analog: Protective mechanisms and long-term effects on neurological recovery. Brain Behav. 2017, 7, e00688. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Li, Z.; Fan, M.; Jin, W. Lipoxins in the Nervous System: Brighter Prospects for Neuroprotection. Front. Pharmacol. 2022, 13, 781889. [Google Scholar] [CrossRef] [PubMed]
- Labianca, R.; Sarzi-Puttini, P.; Zuccaro, S.M.; Cherubino, P.; Vellucci, R.; Fornasari, D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin. Drug Investig. 2012, 32 (Suppl. S1), 53–63. [Google Scholar] [CrossRef] [PubMed]
- Ji, R.R. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. Annu. Rev. Pharmacol. Toxicol. 2023, 63, 273–293. [Google Scholar] [CrossRef]
- Cardia, L.; Calapai, F.; Mondello, C.; Quattrone, D.; Sorbara, E.E.; Mannucci, C.; Calapai, G.; Mondello, E. Clinical use of omega-3 fatty acids in migraine: A narrative review. Medicine 2020, 99, e22253. [Google Scholar] [CrossRef]
- Jin, H.; Li, Y.H.; Xu, J.S.; Guo, G.Q.; Chen, D.L.; Bo, Y. Lipoxin A4 analog attenuates morphine antinociceptive tolerance, withdrawal-induced hyperalgesia, and glial reaction and cytokine expression in the spinal cord of rat. Neuroscience 2012, 208, 1–10. [Google Scholar] [CrossRef]
- Miao, G.S.; Liu, Z.H.; Wei, S.X.; Luo, J.G.; Fu, Z.J.; Sun, T. Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-κB/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation. Neuroscience 2015, 300, 10–18. [Google Scholar] [CrossRef]
- Martini, A.C.; Berta, T.; Forner, S.; Chen, G.; Bento, A.F.; Ji, R.-R.; Rae, G.A. Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection. J. Neuroinflammation 2016, 13, 75. [Google Scholar] [CrossRef]
- Chávez-Castillo, M.; Ortega, Á.; Cudris-Torres, L.; Duran, P.; Rojas, M.; Manzano, A.; Garrido, B.; Salazar, J.; Silva, A.; Rojas-Gomez, D.M.; et al. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy? Int. J. Mol. Sci. 2021, 22, 10370. [Google Scholar] [CrossRef] [PubMed]
- Wei, L.-L.; Shen, Y.-D.; Zhang, Y.-C.; Hu, X.-Y.; Lu, P.-L.; Wang, L.; Chen, W. Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer’s disease. Neurosci. Bull. 2010, 26, 77–84. [Google Scholar] [CrossRef] [PubMed]
- Johansson, J.U.; Woodling, N.S.; Shi, J.; Andreasson, K.I. Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer’s Disease. Curr. Immunol. Rev. 2015, 11, 125–131. [Google Scholar] [CrossRef] [PubMed]
- Kihara, Y.; Matsushita, T.; Kita, Y.; Uematsu, S.; Akira, S.; Kira, J.-I.; Ishii, S.; Shimizu, T. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl. Acad. Sci. USA 2009, 106, 21807–21812. [Google Scholar] [CrossRef] [PubMed]
- Wienecke, T.; Olesen, J.; Oturai, P.S.; Ashina, M. Prostaglandin E2(PGE2) induces headache in healthy subjects. Cephalalgia 2009, 29, 509–519. [Google Scholar] [CrossRef] [PubMed]
- Harder, A.V.; Onderwater, G.L.; van Dongen, R.M.; Heijink, M.; van Zwet, E.W.; Giera, M.; Maagdenberg, A.M.v.D.; Terwindt, G.M. Prostaglandin-E2 levels over the course of glyceryl trinitrate provoked migraine attacks. Neurobiol. Pain. 2022, 13, 100112. [Google Scholar] [CrossRef] [PubMed]
- Antonova, M.; Wienecke, T.; Olesen, J.; Ashina, M. Pro-inflammatory and vasoconstricting prostanoid PGF2α causes no headache in man. Cephalalgia 2011, 31, 1532–1541. [Google Scholar] [CrossRef]
- Sarchielli, P.; Alberti, A.; Codini, M.; Floridi, A.; Gallai, V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000, 20, 907–918. [Google Scholar] [CrossRef]
- Mohammadian, P.; Hummel, T.; Arora, C.; Carpenter, T. Peripheral Levels of Inflammatory Mediators in Migraineurs During Headache-free Periods. Headache J. Head Face Pain 2001, 41, 867–872. [Google Scholar]
- Li, C.; Zhu, Q.; He, Q.; Wang, J.; Wang, F.; Zhang, H. Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2017, 23, 24–28. [Google Scholar] [CrossRef]
- Gürger, M.; Atescelik, M.; Yilmaz, M.; Yildiz, M.; Kalayci, H.; Kobat, M.A.; Demir, C.F. Can we define migraine patients with blood high-sensitivity C-reactive protein and galectin-3 levels in the emergency department? Arch. Med. Sci. 2018, 14, 307–312. [Google Scholar] [CrossRef]
- Park, C.G.; Lee, S.H.; Chu, M.K. No change in interictal C-reactive protein levels in individuals with episodic and chronic migraine: A case-control study and literature review. Front Neurol. 2022, 13, 1021065. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.H.; Kim, J.H.; Kwon, Y.S.; Sohn, J.H. Role of Peripheral Inflammatory Markers in Patients with Acute Headache Attack to Differentiate between Migraine and Non-Migraine Headache. J. Clin. Med. 2022, 11, 6538. [Google Scholar] [CrossRef] [PubMed]
- Yazar, H.O.; Yazar, T.; Aygün, A.; Kaygisiz, Ş.; Kirbaş, D. Evaluation of simple inflammatory blood parameters in patients with migraine. Ir. J. Med. Sci. 2020, 189, 677–683. [Google Scholar] [CrossRef]
- Tietjen, G.E.; Khubchandani, J.; Herial, N.; Palm-Meinders, I.H.; Koppen, H.; Terwindt, G.M.; A Van Buchem, M.; Launer, L.J.; Ferrari, M.D.; Kruit, M.C. Migraine and vascular disease biomarkers. A population-based study. Cephalalgia 2011, 31, 11–12. [Google Scholar]
Migraine Group | n (%) |
---|---|
Family history | |
positive | 31 (58%) |
negative | 22 (42%) |
Aura | |
with | 21 (40%) |
without | 32 (60%) |
Disease duration (years) | |
≤5 | 26 (49%) |
>5 | 27 (51%) |
Headache frequency (per month) | |
≤4 | 21 (40%) |
>4 | 32 (60%) |
Attack duration (hours) | |
<12 | 21 (40%) |
≥12 | 32 (60%) |
White matter lesions | |
Positive | 17 (32%) |
Negative | 36 (68%) |
MIDAS score | |
Mild | 38 (72%) |
Severe | 15 (28%) |
Total | 53 (100) |
Migraine Attack Group 1 Median (Q1;Q3) | Migraine Interictal Group 2 Median (Q1;Q3) | Healthy Control Group 3 Median (Q1;Q3) | 1–2 p * | 1–3 p * | 2–3 p * | |
---|---|---|---|---|---|---|
PGE2, pg/mL | 257 (207; 358) | 218 (180; 296) | 577 (294; 1094) | 0.016 | <0.001 | <0.001 |
LXA4, ng/mL | 22.1 (16.4; 43.6) | 21.8 (17.3; 35.6) | 63.1 (31.1; 144) | 0.196 | <0.001 | <0.001 |
Fibrinogen, g/L | 285 (251; 348) | 294 (266; 348) | 304 (267; 370) | 0.557 | 0.199 | 0.150 |
CRP, mg/dL | 1.54 (0.78; 3.9) | 1.95 (0.73; 4.22) | 1.45 (0.80; 2.7) | 0.538 | 0.558 | 0.558 |
PGE2, pg/mL | LXA4, ng/mL | ||||
---|---|---|---|---|---|
Migraine Interictal Group | n (%) | Median (Q1; Q3) | p Value | Median (Q1; Q3) | p Value |
Family history | |||||
positive | 31 (58%) | 210 (179–367) | 0.576 | 23 (18; 43) | 0.386 |
negative | 22 (42%) | 236 (177–285) | 20 (16; 29) | ||
Aura | |||||
with | 21 (40%) | 212 (180–287) | 0.827 | 22 (18–36) | 0.461 |
without | 32 (60%) | 222 (180–303) | 19 (16–37) | ||
Disease duration (years) | |||||
≤5 | 26 (49%) | 211 (179–317) | 0.722 | 20 (16–43) | 0.783 |
>5 | 27 (51%) | 220 (179–292) | 22 (17–30) | ||
Headache frequency (per month) | |||||
≤4 | 21 (40%) | 212 (173–262) | 0.434 | 22 (16–30) | 0.519 |
>4 | 32 (60%) | 219 (182–351) | 21 (17–40) | ||
Attack duration (hours) | |||||
<12 | 21 (40%) | 241 (206–477) | 0.028 | 25 (20–54) | 0.009 |
≥12 | 32 (60%) | 207 (166–248) | 19 (16–25) | ||
White matter lesions | |||||
Positive | 17 (32%) | 231 (205–318) | 0.230 | 25 (19–40) | 0.286 |
Negative | 36 (68%) | 209 (168–270) | 19 (16–30) | ||
MIDAS score | |||||
Mild | 38 (72%) | 209 (178–240) | 0.710 | 20 (16–31) | 0.248 |
Severe | 15 (28%) | 276 (192–589) | 25 (18–44) | ||
Total | 53 (100) |
PGE2, pg/mL | LXA4, ng/mL | |
---|---|---|
Cut-off Value | 332.7 | 27.2 |
Area Under the ROC Curve (95% Confidence Interval) | 0.759 (0.66–0.85) | 0.801 (0.71–0.89) |
p Value | <0.001 | <0.001 |
Sensitivity | 74% | 81% |
Specificity | 81% | 70% |
Positive Predictive Value | 80% | 73% |
Negative Predictive Value | 77% | 79% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kocaturk, I.; Gulten, S.; Ece, B.; Kukul Guven, F.M. Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies. Diagnostics 2024, 14, 635. https://doi.org/10.3390/diagnostics14060635
Kocaturk I, Gulten S, Ece B, Kukul Guven FM. Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies. Diagnostics. 2024; 14(6):635. https://doi.org/10.3390/diagnostics14060635
Chicago/Turabian StyleKocaturk, Idris, Sedat Gulten, Bunyamin Ece, and Fatma Mutlu Kukul Guven. 2024. "Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies" Diagnostics 14, no. 6: 635. https://doi.org/10.3390/diagnostics14060635